Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyKaiser Permanente SIRT Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedKaiser PermanentePolicy N/A

    Clinical Review Criteria Radioembolization & Chemoembolization Procedures

    Customize your policy alerts

    Sign up for all Kaiser Permanente policy alerts

    Know when Kaiser Permanente releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity review and coverage of yttrium-90 microsphere radioembolization, including TheraSphere and SIR-Spheres, and transcatheter arterial chemoembolization for Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. members and providers.

    Policy Summary
    PayerKaiser Permanente
    PolicyRadioembolization & Chemoembolization Procedures
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateDecember 1, 2026
    Last ReviewApr 7, 2026
    Next Review DateN/A
    Key ActionFor TACE requests, use MCG Clinical Guidelines criterion A-1075 for medical-necessity review.
    SourceLink
    POLICY UPDATE CHANGES

    Transcatheter arterial chemoembolization medical-necessity determinations now use MCG guideline A-1075.

    The Medical Policy Committee approved adoption of new MCG medical-necessity criteria for transcatheter arterial chemoembolization (TACE).

    The applicable code list was updated on February 16, 2022.

    The coverage-article link was updated on November 13, 2023 because article A52950 was retired.

    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered SIRT indication pathways
    6 monthsClinical notes requested
    Any otherSIRT indications not covered
    12/01/2026Effective date for MCG TACE criteria

    Coverage Criteria

    SIRT / yttrium-90 microsphere radioembolization

    Covered when ONE of the following is met.

    Covered SIRT indications

    • Colorectal cancer pathway: The patient has unresectable metastatic liver tumors from primary colorectal cancer.
    • Neuroendocrine tumor pathway

      • Diffuse and symptomatic disease: The disease is diffuse and symptomatic.

        Diffuse means tumor tissue spread throughout the affected organ, such as diffuse liver disease.

      • Failed octreotide therapy: The patient has failed systemic therapy with octreotide to control carcinoid syndrome, such as debilitating flushing, wheezing, and diarrhea.

    Transcatheter arterial chemoembolization

    Medical necessity is determined using the referenced MCG guideline.

    TACE medical-necessity review: Transcatheter arterial chemoembolization is subject to medical-necessity review using MCG Clinical Guidelines criterion A-1075.

    The detailed MCG criteria are accessed through the provider portal under Quick Access and are not reproduced in this document.

    General medical-necessity requirement

    Considered medically necessary when criteria in the applicable policy statements are met.

    Applicable policy criteria: The procedure must satisfy the criteria in the applicable policy statements.

    The detailed criteria are located in policy sections outside this document window.

    Yttrium-90 microsphere radioembolization is not covered for indications other than the specified pathways: unresectable metastatic liver tumors from primary colorectal cancer, or unresectable liver-only or liver-dominant neuroendocrine tumor metastases that are diffuse and symptomatic after failure of systemic octreotide therapy to control carcinoid syndrome.

    The use of TheraSphere to treat unresectable hepatocellular carcinoma does not meet the applicable Kaiser Permanente Medical Technology Assessment Criteria.

    The use of SIRSphere to treat unresectable hepatocellular carcinoma does not meet the applicable Kaiser Permanente Medical Technology Assessment Criteria.

    For Medicare members, services that do not meet the medical-necessity requirements of the applicable yttrium-90 microsphere guidance require medical-necessity review and may be denied when the applicable criteria are not supported. Continue to use LCA A52950 to determine medical necessity.

    TheraSphere treatment for unresectable hepatocellular carcinoma is not supported as meeting the applicable Kaiser Permanente Medical Technology Assessment Criteria.

    SIRSphere treatment for unresectable hepatocellular carcinoma is not supported as meeting the applicable Kaiser Permanente Medical Technology Assessment Criteria.

    Applicable Codes and Medical-Necessity References

    Medicare medical-necessity referencesmixed
    20.28Therapeutic Embolization
    A52950Treatment with Yttrium-90 Microspheres
    TACE medical-necessity guidelinemixed
    A-1075Transcatheter Arterial Chemoembolization (TACE) MCG
    Applicable CodesmixedCovered
    C2616Brachytherapy source, nonstranded, yttrium-90, per source.
    Q3001Radioelements for brachytherapy, any type, each.
    S2095Transcatheter occlusion or embolization for tumor destruction, percutaneous, any method, using yttrium-90 microspheres.
    37243Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction.
    75894Transcatheter therapy, embolization, any method, radiological supervision and interpretation.

    Authorization, Documentation, and Review Requirements

    Prior Authorization

    Medical-Necessity Review Required

    Requests for Medicare members require medical-necessity review using the applicable CMS/Noridian guidance, including LCA A52950 for Yttrium-90 microspheres. For non-Medicare members, review SIRT requests against the covered indications and use the applicable TACE medical-necessity pathway.

    • Medicare: Continue using LCA A52950 to determine medical necessity despite its retirement.
    • SIRT: Review TheraSphere and SIR-Sphere requests against the specified criteria.
    • TACE: Through November 30, 2026, the code is reviewed for medical necessity; beginning December 1, 2026, use TACE A-1075 MCG criteria available through the provider portal.
    Prior Authorization

    Verify Code-Specific Authorization

    Before submitting a request, verify authorization requirements for the specific billed code and the member’s plan type using Kaiser Permanente’s Pre-authorization Code Check.

    • Check each applicable CPT or HCPCS code individually.

    Clinical Background

    Radioembolization is a catheter-based intra-arterial treatment that delivers yttrium-90 microspheres to liver tumors through the hepatic artery. TheraSphere uses glass microspheres and SIR-Spheres uses resin microspheres; both emit localized beta radiation and remain implanted after administration.

    Definitions

    Definitions
    TermDiffuse disease
    DefinitionTumor tissue spread throughout the affected organ.
    ExampleDiffuse liver disease.
    Definitions
    TermSIRT
    Full nameSelective internal radiation therapy.
    Treatment materialYttrium-90 (90Y) microspheres.
    Products
    Policy Summary
    PayerKaiser Permanente
    PolicyRadioembolization & Chemoembolization Procedures
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateDecember 1, 2026
    Last ReviewApr 7, 2026
    Next Review DateN/A
    Key ActionFor TACE requests, use MCG Clinical Guidelines criterion A-1075 for medical-necessity review.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Codes and Medical-Necessity ReferencesAuthorization, Documentation, and Review RequirementsClinical BackgroundDefinitions
  1. Use the provider portal’s Pre-authorization Code Check for plan-specific requirements.
  2. Unsupported block type: documentation

    Documentation Required

    Document Medical Necessity and Authorization

    Submit documentation demonstrating that the applicable medical-necessity criteria are met, and separately verify authorization requirements for the specific code and plan type before the service is performed.

    • Documentation must support the applicable Medicare, SIRT, or TACE criteria.
    • Authorization requirements can vary by code and plan type; confirm them through the Pre-authorization Code Check.
    Denial Risk

    Unlisted SIRT Indications Are Not Covered

    Yttrium-90 microsphere radioembolization is not covered for indications outside the specified covered pathways because clinical utility has not been established.

    • Covered SIRT pathways include unresectable metastatic liver tumors from primary colorectal cancer.
    • A second pathway covers unresectable liver-only or liver-dominant neuroendocrine tumor metastases only when all stated criteria are met.
    • Do not assume coverage for other diagnoses or indications.
    Denial Risk

    Complete Neuroendocrine Tumor Criteria

    For neuroendocrine tumor metastases, the request must document both diffuse, symptomatic disease and failure of systemic octreotide therapy to control carcinoid syndrome.

    • Diffuse means tumor tissue is spread throughout the affected organ, such as diffuse liver disease.
    • Symptoms may include debilitating flushing, wheezing, or diarrhea associated with carcinoid syndrome.
    • Both criteria are required; incomplete documentation may result in noncoverage.
    Prior Authorization

    Use Required Review Guidance

    Use the cited guidance when requesting Medicare radioembolization or TACE services. Medicare requests must continue to be assessed using LCA A52950, while TACE requests must follow the applicable current or future Kaiser Permanente guidance.

    • For Medicare Yttrium-90 services, use Noridian LCA A52950 for medical-necessity determinations.
    • For TACE, use the applicable Kaiser Permanente pathway: current review requirements through November 30, 2026, and TACE A-1075 MCG beginning December 1, 2026.
    Denial Risk

    TheraSphere for Unresectable HCC

    The use of TheraSphere for treatment of unresectable hepatocellular carcinoma does not meet Kaiser Permanente Medical Technology Assessment Criteria.

    • Requests for this indication may be denied based on the assessment-criteria determination.
    Denial Risk

    SIR-Sphere for Unresectable HCC

    The use of SIR-Sphere for treatment of unresectable hepatocellular carcinoma does not meet Kaiser Permanente Medical Technology Assessment Criteria.

    • Requests for this indication may be denied based on the assessment-criteria determination.
    Denial Risk

    Avoid Criteria and Code-Validity Denials

    If the applicable medical-necessity criteria are not met, the service may be denied. Billing an invalid, deleted, or non-current code can also result in noncoverage.

    • Confirm that the code is valid and in effect on the date of service.
    • Codes listed in the policy may not be all-inclusive; verify the code and plan-specific authorization requirements before billing.
    • S codes are not covered by Medicare.
    TheraSphere and SIR-Spheres.